In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...

Regeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa that is exploring the use of digital biomarkers to track patients with ...

The Seattle Mariners are in agreement with free-agent infielder Jorge Polanco on a one-year, $7.75 million deal, two league sources told The Athletic on Thursday, offering some clarity during the ...

Near the end of January, the Mariners reacquired 2024 starting second baseman Jorge Polanco on a one-year, $7.75 million deal with the potential to be worth more than $11 million with incentives.

And the solution is a familiar face. The Mariners signed Jorge Polanco to a one-year deal worth $7.75 million, pending a physical. The deal includes a vesting player/mutual option with a $750,000 ...

The Mariners are bringing back Jorge Polanco. Seattle is reportedly in agreement with the veteran infielder on a one-year deal, pending a physical, that guarantees $7.75MM and includes a vesting ...

There's a new Little Debbie product coming to town, and the internet is already counting down to the mashup of two iconic flavors—peanut butter and chocolate. The snack brand unveiled its latest ...

An MLB source with knowledge of the situation confirmed that Jorge Polanco has reached an agreement with the Mariners on a one-year contract for $7.75 million pending a physical. The contract also ...